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Mouse mast cells can be assigned to two subclasses, defined as connective
tissue-type, and mucosal-type, mast cells. Mucosal-type mast cells can be distin-
guished from connective tissue-type mast cells by their anatomical location,
histochemical staining properties (1), and T cell dependence for proliferation
during a helminthic infection (2). Mouse serosal mast cells (SMC)t, which are
connective tissue-type mast cells, express on their surface the neutral glycosphin-
golipid globopentaosylceramide (which contains the Forssman epitope) (3), and
contain in their secretory granules protease-resistant heparin proteoglycans of
^-750,400 Mf (4, 5). Although definitive biochemical data are not available, as
assessed by their histochemical staining properties (1), mouse intestinal mucosal
mast cells contain little or no heparin proteoglycans.
In 1981, several laboratories reported (6-10) that cells that possessed the
phenotypic characteristics of mast cells could be grown from mouse hemato-
poietic progenitors in the presence of conditioned medium containing T cell-
derived soluble factors. These cultured mast cells exhibited a number ofsimilar-
itiesto mousemucosalmastcells, includingalcian blue-positive/safranin-negative
histochemical staining properties and dependence on T cell factors for their
growth. The mouse bone marrow-derived mast cells (BMMC), when cultured in
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Con A/splenocyte-conditioned medium, WEHI-3 conditioned medium, or pu-
rified IL-3, preferentially synthesize and store in their secretory granules proteo-
glycans of ^-200,000 M, that contain chondroitin sulfate E glycosaminoglycans
(4). Only small amounts of proteoglycans that bear heparin glycosaminoglycans
are detectable in these cells (11). BMMC do not have detectable amounts of
globopentaosylceramide, but express on their surface the probable precursor of
this glycosphingolipid, globotetraosylceramide (globoside) (12). When cocultured
on mouse skin-derived 3T3 fibroblasts, the in vitro-derived BMMC become
more similar to connective tissue mast cells than to mucosal mast cells in that
they become alcian blue-positive/safranin-positive, increase their histamine con-
tent ~I 5-fold, synthesize considerably more proteoglycans bearing heparin gly-
cosaminoglycans (13), and increase their expression of the Forssman epitope (our
unpublished observations).
A possible lineal relationship between mucosal-type mast cells and connective
tissue-type SMC has been indicated by in vivo studies (14, 15) in which the
subclasses of mast cells detected in mast cell-deficient mice after adoptive transfer
of BMMC were defined by their tissue location and staining properties. When
alcian blue-positive/safranin-negative/berberine sulfate-negative BMMC from
WBB6F,±/+ mice were injected into the peritoneal cavities of mast cell deficient
WBB6F,-W/W" mice, the resultant SMC that were recovered after 10 wk con-
tained ^-20 times more histamine than did the BMMC and contained granules
that were alcian blue-positive/safranin-positive/berberine sulfate-positive (14).
BMMC that contained abnormally large granules derived from C57BL/6-bgJ/bgJ
(beige) mutant mice were used to confirm that the SMC appearing in mast cell-
deficient recipients were of donor origin. That the mast cells in the glandular
stomach mucosa of the reconstituted animals stained with alcian blue but not
with berberine sulfate or safranin indicated that the tissue microenvironment
regulated the mast cell phenotype. Moreover, in vivo studies have also revealed
that partially purified (14) or single (15) SMC can give rise to cells with phenotypic
characteristics of both subclasses of mast cells after injection into WBB6F,-W/W"
mice.
In the present study, we demonstrate that T cell factor-dependent cultured
mouse BMMC injected into the peritoneal cavities of WBB6F,-W/W" mice
undergo phenotypic biochemical changes that are characterized by a marked
increase in the biosynthesis ofheparin proteoglycans and in the surface expression
of the Forssman epitope of globopentaosylceramide.
Materials and Methods
Materials. Penicillin, streptomycin, PWM, RPMI 1640, and DME (Grand Island
Biological Co., Grand Island, NY); horse serum (Sterile Systems, Inc., Logan, UT); FCS
(Irvine Scientific, Santa Ana, CA); a medium (Flow Laboratories, Inc., Irvine, Scotland);
Sephadex G-25/PD-10 gel filtration columns and Sepharose CL-4B (Pharmacia Fine
Chemicals, Piscataway, NJ); 'H-labeled heparin (0.08 mCi/mg) and ["S]sulfate (^-4,000
Ci/mmol) (New England Nuclear, Boston, MA); Partisil-10 PAC amino-cyano HPLC
columns (Whatman Inc., Clifton, NJ); Hydrofluor (National Diagnostics, Somerville, NY);
1,2-dimethoxyethane and butyl nitrite (Eastman Kodak Co., Rochester, NY); heparin
(Sigma Chemical Co., St. Louis, MO); Zwittergent 3-12 (Calbiochem-Behring Corp., La
Jolla, CA); chondroitin sulfate A, chondroitin sulfate C, Flavobacterium heparinum hepa-
rinase, Proteus vulgaris chondroitinase ABC, Proteus vulgaris chondro-6-sulfatase, ProteusOTSU ET AL.
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vulgaris chondro-4-sulfatase, ODi-OS, ADi-4S, and ODi-6S (Miles Laboratories Inc ., Elk-
hart, IN); and fluorescein-conjugated F(ab')2 fragments of affinity-purified goat anti-rat
!FM (CooperBiomedical, Inc ., Malvern, PA) were obtained as noted. Rat chondrosarcoma
s S'-labeled proteoglycan (M, . = -2 x 10 6 ) was prepared as previously described (16) . The
unsaturated "S-labeled disaccharide, ADi-diS E , was obtained by chondroitinase ABC
treatment of "'S-labeled mouse BMMC proteoglycan (4) .
Mice.
￿
Mast cell-deficient WBB6F,-W/W" mice (having no detectable SMC and <1%
of the normal number of skin connective tissue mast cells [17]) and WBB6F,*/+ mice
were raised to 2-6 mo old at the Osaka University Medical School and the Shizuoka
Laboratory Animal Center, Japan . The original stocks of parental strains (i.e ., WB-W/+
and C57BL/6-W"/+) were obtained from The Jackson Laboratory (Bar Harbor, ME) .
The WB-W/+ strain was maintained by brother-sister matings, but the W" mutant gene
was maintained in C57BL/6 mice of the Osaka University inbred colony for more than
30 backcrosses.
Culture of T Cell Factor-dependent Mouse BMMC .
￿
Mouse bone marrow cells were
suspended at a concentration of 106/ml in a medium supplemented with 10-4 M 2-ME,
20% horse serum, and 10% PWM-stimulated spleen cell-conditioned medium as described
previously (14) . The conditionedmedium was prepared by incubating spleen cells for 5 d
at 2 X 106 cells/ml in a medium containing a 1 :300 dilution of pokeweed mitogen, 10%
FCS, and 10-4 M 2-ME. After centrifugation, the conditioned medium was filtered
through 0.45 tem filters and stored at -80°C . Cells were maintained in a humidified
atmosphere of 5% C02 for 4-7 wk, and the non-adherent cells were placed into fresh
culture media every 7 d . At a time when the mast cell purity exceeded 95% as assessed
histochemically, the BMMC were washed and 106 BMMC in 1 .0 ml of a medium were
injected intraperitoneally per mouse .
Purification of Serosal Mast Cells.
￿
For each experiment, the mast cells were isolated
from the peritone4l c~yities of,4Q-50 WBB6F,~/+ mice and WBB6F,-W/W"mice injected
15 wk earlier with WBB6F,+/+-derived BMMC . Tyrode's buffer with gelatin (TG ; 2 ml)
was injected into the peritoneal cavity ofeachmouse . After gentle massage of theabdomen
for -30 s, the peritoneal cavity was opened, and the fluid containing the SMC was
aspirated . The cells from groups of 10 mice were pooled, centrifuged at 150 g for 10 min
at room temperature, resuspended in 1 ml of TG, and layered over 2 ml of 22.5%
metrizamide . After centrifugation at 350 g for 15 min at room temperature, the mast
cells were harvested at the bottom of the tube . The mast cell purity after a single
metrizamide gradient sedimentation was 70-80%, and these cells were used routinely for
biochemical analyses . The purity of the mast cells was >95% after a second metrizamide
gradient sedimentation, and this latter population of cells was used for cytofluorographic
analysis. Serosal and cultured mast cells were quantified using a hemocytometer after
staining with neutral red (0.02% in 0.9% NaCl).
[55S]Sulfate Labeling ofMast CellsandPurification of "S-labeled Proteoglycans .
￿
Purified
mouse SMC and BMMC (2-10 X 106 cells) were suspended either in sulfate-free RPMI
1640 or in a 1 :3 mixture of normal and sulfate-free RPMI 1640 containing 10% FCS at
a concentration of 106 cells/ml . ["S]Sulfate (100 pCi/ml) was added, and the cell suspen-
sions were incubated for 3-20 h at 37°C in 5% C02 . The 3'S-labeled mast cells were
pelleted by centrifugation at 150 g, washed three times with RPMI 1640 medium, and
then disrupted by the addition of 500 eel of 4 M guanidine-HCI containing 0.1% Zwitter-
gent 3-12 and sufficient solid CsCl to achieve a final density of 1 .4 g/ml (4) . Porcine
heparin glycosaminoglycan (0 .1 mg) was routinely added asa carrier to prevent nonspecific
loss of '5S-labeled proteoglycans . Samples were centrifuged at 17°C for 48 h at 100,000
g using a SW40-Ti rotor (Beckman Instruments, Inc., Fullerton, CA) (18) . The bottom
50% of each gradient was dialyzed against 0.1 M NH4HCOs , lyophilized, and then
redissolved in distilled water.
Gel Filtration Chromatography of "S-labeled Mast Cell Proteoglycans before and after
Treatment with Either Pronase or NaOH. The approximate M, of the density gradient-
purified "S-labeled mast cell proteoglycans before and after either Pronase (19) or alkaline
treatment (4) was determined by Sepharose CL-4B chromatography. For Pronase diges-61 8
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tion, 20 P.1 of 10 mg/ml Pronase and 30 Al of 0.25 M Tris-HCI, pH 8 .0, were added to
100-Al samples ofdensity gradient-purified mast cell "S-labeled proteoglycans containing
2-5 X 10' cpm . After a 1-h incubation at 37°C, 250,l of distilled water and 400 AI of 8
M guanidine-HCI/0 .2 M sodium sulfate/0.2 M Tris-HCI, pH 7 .0, were added to each
Pronase digest . Replicate 100-P,I samples were incubated at 22° C for 20 h in 0.2M NaOH
to remove the glycosaminoglycan side chains from the "S-labeled proteoglycans via (3
elimination . After neutralization with acetic acid, the samples were mixed with 300 Al of
distilled water and 400 Al of 8 M guanidine-HCI/0 .2 M sodium sulfate/0.2 M Tris-HCI,
pH 7 .0 . Native, Pronase- and alkali-treated "S-labeled proteoglycan samples were applied
separately to 0.8 X 90-cm columns of Sepharose CL-4B that had been previously equili-
brated with 0.1 M Tris-HCI, 0.1 M Na2SO4 , and 4 M guanidine-HCI, pH 7 .0 (TSG
buffer) . The Sepharose CL-4B columns were eluted at a flow rate of 5 ml/h, and 0.9 ml
fractions were collected . Each fraction was mixed with 0.9 ml of ethanol and 10 ml of
Hydrofluor, and the radioactivities were quantified using a Tracor Analytic Mark III
liquid scintillation counter .
Characterization of the "S-labeled Glycosaminoglycans Bound to Mast Cell Proteogly-
cans . "S-Labeled proteoglycans isolated from the different populations of mast cells
were resuspended in 500 Al of water, and 100-PI samples were incubated with chondroi-
tinase ABC (20, 21), heparinase (22), or nitrous acid (23) . The resulting samples and
untreated material were chromatographed on Sephadex G-25/PD-10 columns to deter-
mine the nature of the "S-labeled glycosaminoglycans bound to the different proteoglycan
samples by following the shift in radioactivity from the excluded to the included volumes .
For the control samples, 100 Al of each preparation was suspended in 400 AI of TSG
buffer containing 200 Ag of heparin glycosaminoglycan carrier . To determine the suscep-
tibility to degradation by chondroitinase ABC, preparations were suspended in 250 JAI
(final volume) of Tris-enriched buffer (20) containing 10 mM NaF and 200 Ag of
chondroitin sulfate A, and were incubated at 37'C for 30 min with 0.5 U of chondroitinase
ABC . To determine the susceptibility to degradation by heparinase, preparations were
suspended in 250 AI (final volume) of 0.1 M sodium acetate buffer, pH 7.0, containing 1
mM calcium acetate, 0.1% toluene, 100 tag of heparin, and ^-30 mU of heparinase, and
then were incubated at 37 °C for 16 h . To determine the susceptibility to degradation by
nitrous acid, 100-P1 samples were incubated with 12.5 Al of butyl nitrite, 125 P,1 of 1,2-
dimethoxyethane, and 200 wg of heparin for 17 h at -20'C . At the end of the chondroi-
tinase ABC, heparinase, and nitrous acid treatments, 250 Al of 8M guanidine-HCI/0 .2 M
sodium sulfate/0.2 M Tris-HCI, pH 7.0, was added to each mixture . All samples were
then applied to separate Sephadex G-25/PD-10 columns that had been equilibrated with
TSG buffer . The columns were eluted with TSG buffer, and 0.5-ml fractions were
collected, mixed with 0.5 ml of ethanol and 10 ml of Hydrofluor, and the radioactivity
was determined.
The nature of the "S-labeled unsaturated disaccharides liberated by chondroitinase
ABC treatment of the "S-labeled mast cell proteoglycans was determined by HPLC as
described by Seldin et al . (24) . Replicate samples of each "S-labeled proteoglycan prepa-
ration were incubated as described above with chondroitinase ABC alone ; chondroitinase
ABC and 0.5 U chondro-6-sulfatase; or chondroitinase ABC, 0.5 U chondro-6-sulfatase,
and 0.5 U chondro-4-sulfatase . At the end of each digestion, 1 .2 ml of ethanol was added,
and the samples were placed on ice for 1 h and centrifuged at 8,000 g for 10 min at 4°C .
The supernatants were dried under a stream of nitrogen, suspended in 100 A1 of 70%
acetonitrile/methanol (3 :1, vol/vol) and 30% 0.5 M ammonium acetate/acetic acid, pH
5 .3, and chromatographed on a 4.6 X 250 mm Partisil-10 column at a flow rate of 1
ml/min . The radioactivity in each 0.5-ml fraction was determined by liquid scintillation
counting . The HPLC column was standardized with the unsaturated chondroitin sulfate-
derived disaccharides ODi-OS, ADi-4S, ADi-6S, and ODi-diS E .
Analysis of Cell Surface Expression ofthe Forssman Epitope.
￿
The rat IgM mAb B1 .1 (3)
was used to evaluate the expression of the Forssman epitope on the cell surface of the
different populations of mast cells . A rat monoclonal IgM anti-TNP antibody (RATNP
17.3) (obtained from Dr. P . A . LeBlanc, University of Alabama, Tuscaloosa, AL) wasOTSU ET AL.
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used as a control reagent. Replicate samples of 5 X 105 BMMC, SMC harvested from
WBB6F,-+/+ mice, and SMC recovered from WBB6F,-W/W" mice that had been reconsti-
tuted with BMMC were each placed in 1.5-ml polypropylene conical-bottomed centrifuge
tubes with calcium- and magnesium-free HBSS containing 0.1% BSA and 0.02% sodium
azide (HBA). The cells were centrifuged at 1,000 g for 1 min, and replicate pellets of
each cell preparation were incubated in an ice bath for 30 min with 50 pal of either the
B1 .1 or the RATNP 17.3 mAb (350 Ag IgM/ml). An excess of NBA was added, and the
cells were washed twice by centrifugation. 50 ul of fluorescein-conjugated F(ab')2 frag-
ments of affinity-purified goat anti-rat IgM diluted 1:50 in HBA was added to each cell
pellet. The cells were resuspended, incubated in the dark for 30 min in an ice bath,
washed by centrifugation, and resuspended in HBA for flow cytometric analysis on a
FACS IV (Becton Dickinson & Co., Oxnard, CA). Cells positive for the binding of the
B1.1 mAb were definedas those exhibiting channel numbers of fluorescence greater than
those of 97% of the replicatecells interacted with the RATNP 17.3 mAb. The net mean
channel number of fluorescence (a measure of fluorescence intensity) was defined as the
mean channel number of fluorescence of cells stained with B1 .1 antibody minus that of
cells incubated with the RATNP 17 .3 antibody.
Results
Characterization of 35S-labeled Mast Cell Proteoglycans.
￿
The three populations
of mast cells that were analyzed for their cell-associated proteoglycans were the
starting population of BMMC from normal +/+ mice, SMC from +/+ mice, and
SMC that were recovered from the peritoneal cavities of W/W" mice 15 wk after
the injection of BMMC from +/+ mice. After density-gradient centrifugation of
thedetergent/guanidine-HCI lysates of the three populations of "S-labeled mast
cells, in each instance >85% of the 2"S-labeled macromolecules were recovered
in thebottom half ofthe gradients, consistent with the preferential incorporation
of this radioisotope into proteoglycans. Samples of these partially purified
s55-
labeled proteoglycans were chromatographed on a Sepharose CL-4B column
under dissociative conditions to determine their hydrodynamic sizes. Based on
theobtained Ka, values of 0.34 ± 0.035 (mean ± SD, n = 8), 0.26 ± 0.035 (mean
± SD, n = 4), and 0.25 ± 0.05 (mean ± SD, n = 4), it was concluded that the Mi
of the "S-labeled proteoglycans in the starting BMMC (Fig. 1A), the SMC from
the +/+ animals (Fig. 1B), and the SMC recovered from thereconstituted W/W"
animals (Fig. 1 C) were
￿
350,000;
￿
600,000; and
￿
650,000 M,.; respectively.
The 55S-labeled proteoglycans in all studied populations of mast cells were
resistant to degradation by Pronase, since their hydrodynamic size on Sepharose
CL-4B did not change appreciably after enzymatic treatment (Fig. 1, A 'and C).
Characterization of "S-labeled Glycosaminoglycans.
￿
The "S-labeled glycosami-
noglycan side chains from the starting BMMC (Fig. 2A), the SMC from normal
+/+ mice (Fig. 2B), and the SMC from the reconstituted animals (W/W") (Fig.
2C) filtered on Sepharose CL-4B with Kav values of 0.60 ± 0.013 (mean ± SD,
n = 5), 0.49 (n = 1), and 0.51 ± 0.031 (mean ± SD, n = 3), indicative of M, of
55,000 ;
￿
115,000; and
￿
105,000; respectively.
Replicate samples of partially purified mast cell proteoglycans were subjected
to either chondroitinase ABC, heparinase, or nitrous acid treatments, and the
resulting digests were chromatographed on Sephadex G25/PD-10 columns un-
der dissociative conditions to determine the nature of the "S-labeled glycosami-
noglycans. In control experiments, both untreated "S-labeled chondrosarcoma.
chondroitin sulfate proteoglycans and untreated sH-labeled heparin glycosami-620
￿
PHENOTYPIC CHANGES OF BONE MARROW-DERIVED MAST CELLS
FIGURE 1 .
￿
SepharoseCL-4Bchromatography ofthe cell-associated'SS-labeled proteoglycans
from mouse BMMC (A), SMC from +/+ mice (B), and SMC from reconstituted W/W" mice
(C) before (0) and after (O) incubation with Pronase . Vo and V, mark the columns' void
volumesand total volumes, respectively. Data are from a representative experiment .
noglycans eluted in the excluded volumes of the columns . After treatment of the
"S-labeled chondrosarcoma proteoglycans with chondroitinase ABC, 95 ± 1%
(mean ± SD, n = 3) of the radioactivity filtered in the included volume of the
column, whereas after treatment with nitrous acid and heparinase, <4% of the
3'S-labeled proteoglycans filtered in the included volume of the column . After
incubation of the sH-labeled heparin glycosaminoglycan with heparinase, nitrous
acid, and chondroitinase ABC, 79 ± 9%, 89 ± 4%, and 2 ± 1% (mean ± SD, n
= 3) of the radioactivity, respectively, filtered in the included volume of the
columns .
As assessed by Sephadex G25/PD-10 chromatography, 86 ± 11%, 9 ± 11 %,
and 10 ± 11 % (mean ± SD, n = 8) of the 3'S-labeled glycosaminoglycans of the
mouse BMMC that had been differentiated in vitro in the presence of PWM-
conditioned media were degraded by chondroitinase ABC, nitrous acid, and
heparinase, respectively (Fig . 3A) . Three out of eight of these cultures differed
from the BMMC cultures presented in Fig . 3A in that 15-32% of the 3'S-labeled
glycosaminoglycans were degraded as heparin . When analyzed by HPLC, 58 ±
5% and 42 ± 5% (mean ± SD, n = 5) of the "S-labeled unsaturated disaccharides
generated by chondroitinase ABC treatment of theBMMC samples eluted at the
retention times corresponding to the ODi-4S and ODi-diSE standards, respectivelyOTSU ET AL.
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FIGURE 2.
￿
Sepharose CL-4B chromatography of the "S-labeled glycosaminoglycans fl-elim-
inated from the proteoglycans of mouseBMMC (A), SMC from +/+ mice (B), and SMC from
reconstituted WIW" mice (C) . Va and V, mark the columns' void volumes and total volumes,
respectively. Data are from a representative experiment .
(data not shown) . When these "S-labeled proteoglycans from BMMC were
incubated with both chondro-6-sulfatase and chondroitinase ABC, almost all of
the radioactivity associated with the ADi-diSE peak disappeared, whereas the
radioactivity associated with the ODi-4S and free sulfate peaks increased . Incu-
bation of the samples with chondro-6-sulfatase, chondro-4-sulfatase, and chon-
droitinase ABC resulted in the elution of almost all of the radioactivity into the
free [s5S]sulfate peak . Thus, mouse BMMC differentiated in PWM-conditioned
media synthesize proteoglycans that contain primarily chondroitin sulfate E
glycosaminoglycans, although variable amounts of heparin glycosaminoglycans
are also present.
When "S-labeled proteoglycans produced by normal SMC from +/+ mice
were incubated with chondroitinase ABC, nitrous acid, and heparinase, 5± 1%,
82 ± 7%, and 73 ± 6% (mean ± SD, n = 4) of the total macromolecular
radioactivity was degraded (Fig . 3B). The mast cells recovered from the perito-
neal cavities of the reconstituted W/W" mice synthesized 3'S-labeled proteogly-
cans that were degraded 5 + 3%, 84 ± 3%, and 72 ±7% (mean± SD, n = 4) by
chondroitinase ABC, nitrous acid, and heparinase treatments, respectively (Fig .
3C) . Because of the low chondroitin sulfate content of the proteoglycans present622
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FRACT1f~N NUMBER
FiratmE 3. Sephadex G25/PD-10 chromatography of the "S-labeled proteoglycans from
mouse BMMC (A), SMC from +/+ mice (B), and SMC from reconstituted WIWmice (C)
beforeandaftertreatmentwith chondroitinase ABC, nitrousacid,orheparinase. Thenumbers
in parentheses indicate M percentage 4 the total "S-labeled macromolecules that were
degraded by each treatment. Data are from arepresentative experiment.
in SMC, it was not possible to analyze their unsaturated chondroitin sulfate
disaccharides by HPLC.
Immures, uoreseenceAnalysis ofthe Surface Expression ofthe ForssmanEpitope.
￿
As
assessed by indirect immunofluorescence staining and flow cytometric analysisin
two experiments, BMMC were 1.2% (Fig. 4A)and 7.3% positivefor the binding
of the 111.1 rat monoclonal anti-Forssman epitope antibody, with net mean
channel numbers of fluorescence of 2.0 and 5.5, respectively. SMC purified to
-98% from WBI16FI -w}I* mice were 69.7% (Fig. 4B) and 93.5% positive for
B1.1, with net mean channel numbers offluorescence of 34.3 and 44.4, respec-
ively. SMC purified to ~98% from the peritoneal cavities of WBB6F,-W/Wv
15 wk after the injection of BMMC were 75.0% (Fig. 4C) and 68.4%
positive for the bindingof the B1. 1 antibody with net mean channel numbers of
31.
￿
and 5LL respectively.
Discussion
In this report, we demonstrate that when T cell factor-dependent cultur
WBB6F,-'/+ BMMC, which preferentially synthesize -350,000 M, chondroitin
sulfate E proteoglycans and express little of the Forssman epitope, are injectedOTSU ET AL .
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FIGURE 4 .
￿
Flow cytometric analysis of the surface binding of B1 .1 mAb toBMMC (A), SMC
from +/+ mice (B), and SMC from reconstituted W/W" mice (C) . Cells were incubated in
either negative control antibody (---) or B1 .1 antibody (-), washed, incubated with
fluorescein-conjugated F(ab')2 goat anti-rat IgM, and analyzed on aFAGS IV cytofluorograph .
into the peritoneal cavities of genetically mast cell-deficient WBB6F,-W/W" mice,
they give rise to SMC that, like SMC obtained directly from WBB6F,+/+ mice,
preferentially synthesize and store ^-600,000 Mr heparin proteoglycans and
express the Forssman epitope on their cell surface . These findings confirm our
previous morphological and histochemical studies showing that T cell factor-
dependent mouse BMMC can give rise to mast cells with phenotypic character-
istics ofSMC (connective tissue-type mast cells) following injection into mast cell-
deficient WBB6F,-W/W" mice . Whereas no cells in the initial populations of
BMMC had granules that stained detectably with either berberine sulfate or
safranin, berberine sulfate-positive/safranin-positive mast cells developed in
those anatomical sites that in normal mice contain connective tissue mast cells
(e .g ., skin, peritoneal cavity, and gastric muscularis propria) (14) . In contrast,
berberine sulfate-negative/safranin-negative, mucosal-like mast cells developed
in the gastric mucosa of the reconstituted animals . Although theBMMC used in
these original reconstitution studies appeared to be homogeneous morphologi-
cally and histochemically, they were not cloned . More recently, aT cell factor-
dependent population of mast cells was cloned in methylcellulose from cells
derived from the peritoneal cavity of WBB6F,±/+ mice . These cloned mast cells,
which are berberine sulfate-negative/safranin-negative gave rise to berberine
sulfate-positive/safranin-positive SMC 10 wk after they were injected into
WBB6F,-W/W" mice (25) . Further, both subclasses of mast cells were detected
when a single SMC from aWBB6F,+/+ mouse was injected into these mast cell-
deficient mice (15) . That some populations of BMMC in the present study
contained detectable amounts of heparin proteoglycans but did not stain with624
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either safranin or berberine sulfate may reflect a lesser sensitivity of the staining
methods compared to the biochemical techniques.
The chemical definition of the culture-derived BMMC and the phenotypically
altered mast cells recovered after adoptive transfer in mast cell-deficient mice is
also fully consistent with our parallel in vitro studies (13) . Although it has been
reported (4) that T cell factor-dependent BMMC cultured in WEHI-3-condi-
tioned media do not synthesize sufficient amounts ofheparin glycosaminoglycans
to be detected in whole cell extracts, these cells have recently been shown (11)
to synthesize small amounts of heparin proteoglycans and to exocytose them
preferentially in a complex of >107 M, . . The finding that the biosynthesis of
proteoglycans containing heparin glycosaminoglycans is substantially increased
relative to that of proteoglycans containing chondroitin sulfate E glycosamino-
glycans when BMMC are cocultured with mouse 3T3 fibroblasts indicates that
the phenotype of mast cells is in part regulated by connective tissue fibroblasts
(13) .
Recent findings suggest that the different phenotypes of the tissue mast cells
could reflect differential regulation of a limited number of genes . The mRNA
encoding the peptide core of the proteoglycans of mouse BMMC and rat SMC
has been analyzed with a cDNA probe derived from a rat yolk sac tumor cell
(26) that encodes a serine-glycine rich peptide core . These studies revealed a
single, possibly identical, species of mRNA in both mast cell populations (27),
consistent with an interpretation that different subclasses ofmast cellspolymerize
different types of glycosaminoglycans onto a common peptide core . As the
sequences of the initial four monosaccharides of heparin and chondroitin sulfate
E glycosaminoglycans are believed to be the same (28), the regulation of glycos-
aminoglycan biosynthesis may occur through differential expression of the two
glycosyl transferases that mediate the addition of the fifth monosaccharide to
the respective chains . However, differential posttranslational modification of a
common peptide core that in turn directs these proteins to different glycosami-
noglycan-synthesizing compartments in the Golgi, or varied rates of catabolism
of heparin-containing proteoglycans versus chondroitin sulfate-containing pro-
teoglycans could also account for the presence of proteoglycans that preferen-
tially bear either heparin or chondroitin sulfate E glycosaminoglycans in the
secretory granules of the two types of mast cells . The biosynthesis of globopen-
taosylceramide is believed to occur by the addition of a single N-acetyl-galactos-
amine to globotetraosylceramide (29) . Thus, the switch in the expression of
globoside on the cell surface ofBMMC to globopentaosylceramide on the cell
surface of SMC could also occur by the regulation of a single enzymatic step .
Summary
The abilityofmouse IL-3-dependent, bone marrow culture-derived mast cells
(BMMC) to generate serosal mast cells (SMC) in vivo after adoptive transfer to
mast cell-deficient mice has been defined by chemical and immunochemical
criteria . BMMC differentiated and grown from WBB6F,±I+ mouse progenitor
cells in medium containing PWM/splenocyte-conditioned medium synthesized
a ^-350,000 Mr protease-resistant proteoglycan bearing ^-55,000 M, . glycosami-
noglycans, as defined by gel filtration of each . ^-85% of the glycosaminoglycansbound to the cell-associated BMMC proteoglycans were chondroitin sulfates
based upon their susceptibility to chondroitinase ABC digestion; HPLC of the
chondroitinase ABC-generated unsaturated disaccharides revealed these glycos-
aminoglycans to be chondroitin sulfate E. As determined by heparinase and
nitrous acid degradations, ^-10% of the glycosaminoglycans bound to BMMC
proteoglycans were heparin. In contrast, mast cells recovered from theperitoneal
cavity of congenitally mast cell-deficient WBB6F1-W/W" mice 15 wk after
intraperitoneal injection of BMMC synthesized ^-650,000 M, protease-resistant
proteoglycans that contained ^-80% heparin glycosaminoglycans of ^-105,000
M,. Thus, after adoptive transfer, the SMC of the previously mast cell-deficient
mice were like those recovered from the normal WBB6F1+/+ mice that were
shown to synthesize ^"600,000 Mr proteoglycans that contained ^-80% heparin
glycosaminoglycans of
￿
115,000 M,..
As assessed by indirect immunofluorescence staining and flow cytometry using
the B1 .1 rat mAb (an antibody that recognizes an epitope located on the neutral
glycosphingolipid globopentaosylceramide), -5% of BMMC bound the antibody
detectably, whereas -72% of the SMC that were harvested from mast cell-
deficient mice 15 wk after adoptive transfer of BMMC were B1 .1-positive; ^-82%
of SMC from WBB6F,'I ' mice bound the antibody. These biochemical and
immunochemical data are consistent with the results ofprevious adoptive transfer
studies that characterized mast cells primarily on the basis of morphologic and
histochemical criteria. Thus, IL-3-dependent BMMC developed in vitro, cells
that resemble mucosal mast cells, can give rise in vivo to SMC that express
phenotypic characteristics of connective tissue mast cells.
Receivedforpublication 27 October 1986.
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